Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Ibrutinib continues strong showing against mantle cell lymphoma

20.06.2013
Latest results of Phase 2 study confirm high rate of response, remission

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

The most recent interim findings of the 18-center Phase 2 study were published today in the New England Journal of Medicine. Previous interim findings were presented in December 2012 at the 54th American Society of Hematology Annual Meeting and Exposition.

Unprecedented results, fewer side effects

"This oral inhibitor of the Bruton's tyrosine kinase in the B-cell receptor pathway is the most important breakthrough to date in the treatment of mantle cell lymphoma," said Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. Wang is lead author of the trial.

"It is an oral drug, taken once a day, and its side effects are not severe. Yet it can achieve more than previous combination chemotherapy approaches. Our results constitute excellent news for our patients and patients around the world."

The ongoing trial of oral ibrutinib in patients with heavily treated relapsed or refractory MCL has maintained a response rate as high as 70 percent - better than any other single agent ever tested in the challenging disease – with milder side effects than other treatments.

Targeted approach to dangerous disease

MCL is a rare and aggressive B-cell subtype of non-Hodgkin lymphoma that, according to the Leukemia and Lymphoma Society, accounts for 6 percent of non-Hodgkin cases. Despite high response rates to initial highly toxic combination-drug chemotherapy, patients often relapse.

The B-cell receptor pathway is critical in B-cell lymphoma, and Bruton's tyrosine kinase (BTK) is an essential component of this pathway. Ibrutinib targets the BTK molecule, causing cell death and decreasing cellular migration and adhesion in malignant B-cells.

In this study, patients were given 560 mg daily ibrutinib in continuous 28-day cycles until disease progressed or side effects became intolerable. To date, 111 patients have participated in the study.

Seventy-seven percent had stage 4 disease, and the median number of prior treatments was three.

Ongoing results continue to show promise

In the past six months, ibrutinib has continued to show excellent results. With a median follow-up period of 15 months:

Overall response rate was 68 percent
Complete response rate was 21 percent
Partial response rate 47 percent
Response and complete remission rates improved with longer duration of treatment.

Among the 75 patients who responded, median:
Response duration was 18 months
Time to response was two months
Progression-free survival was 14 months
Most side effects were minor and included diarrhea, fatigue, upper respiratory tract infections, nausea and rash. Grade 3 or higher effects included low white cell blood counts, anemia and diarrhea.

Next steps

Wang believes further investigation of ibrutinib as a first line therapy and in combination with other targeted therapies and traditional cytotoxic agents is essential.

"This drug, which is the safest option we have for MCL, shows unprecedented durable single agent activity," he said. "The favorable toxicity profile also implies that ibrutinib provides the opportunity for less intense and more effective regimens. The long-term impact of ibrutinib definitely warrants further clinical testing."

Pharmacyclics, Inc., which developed ibrutinib, sponsored the clinical trial.

Wang's co-authors at MD Anderson include Jorge E. Romaguera, M.D., Liang Zhang, M.D., Ph.D., Kate Newberry, Ph.D., and Zhishuo Ou, M.D., Department of Lymphoma and Myeloma; Lei Li, Ph.D., Department of Experimental Radiation Oncology; and Bingliang Fang, Ph.D., Department of Thoracic and Cardiovascular Surgery.

Other members of the research team include Simon Rule, M.D., Derriford Hospital, Plymouth, United Kingdom; Peter Martin, M.D., Weill Cornell Medical College, New York, New York; Andre Goy, M.D., John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Rebecca Auer, M.D., Ph.D., Barts Health NHS Trust, London, United Kingdom; Brad S. Kahl, M.D., University of Wisconsin, Madison; Wojciech Jurczak, M.D., Ph.D., Jagiellonian University, Krakow, Poland; Ranjana Advani, M.D., Stanford University Medical Center, Stanford, California; Michael E. Williams M.D., University of Virginia School of Medicine, Charlottesville, Virginia; Jacqueline Barrientos, M.D., Department of Medicine, Hofstra North Shore-LIJ, New Hyde Park, New York; Ewa Chmielowska, M.D., Oddzial Kliniczny Onkologii Centrum Onkologii, Bydgoszcz, Poland; John Radford, M.D., The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom; Stephan Stilgenbauer, M.D., Universitatsklinikum Ulm, Klinik fur Innere Medizin II, Ulm, Germany; Martin Dreyling, M.D., Klinikum der Universitat Munchen – Campus Grosshadern, Munich, Germany; Wieslaw Wiktor Jedrzejczak, M.D., Medical University of Warsaw, Poland; Peter Johnson, M.D., Cancer Research UK Centre, University of Southampton, United Kingdom; Stephen E. Spurgeon, M.D., Oregon Health and Science University, Portland, Oregon; Nancy Cheng, M.S., Baylor College of Medicine, Houston, Texas; Jesse McGreivy, M.D., Fong Clow, Sc.D., Joseph Buggy, Ph.D., Betty Chang, Ph.D., Darrin Beaupre, M.D., Ph.D. and Lori A. Kunkel, M.D., Pharmacyclics, Inc., Sunnyvale, CA; and Kristie Blum, M.D., Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Laura Sussman | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Safe glide at total engine failure with ELA-inside

27.02.2017 | Information Technology

Fraunhofer IFAM expands its R&D work on Coatings for protection against corrosion and marine growth

27.02.2017 | Materials Sciences

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>